TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease
Brief Summary: This study is to assess noninferiority in efficacy and to assess overall safety of CT P13 compared to Remicade in patients with active Crohn's disease up to Week 54.


Options:
A: Arm Label: Usual Care practice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Algorithm; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment Algorithm for Crohn's Disease | Intervention Type: OTHER; Name: Treatment Algorithm for Crohn's Disease; Assigned to Arm(s): Treatment Algorithm
B: Arm Label: PRECISION dosing; Type: EXPERIMENTAL; Interventions: Drug: PRECISION dosing Infliximab | Arm Label: Conventional dosing of Infliximab; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: PRECISION dosing Infliximab; Assigned to Arm(s): PRECISION dosing
C: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Biological: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CT-P13 - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: CT-P13 - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13, Biological: Remicade | Arm Label: Remicade - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: Remicade | Arm Label: Remicade - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13, Biological: Remicade | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): CT-P13 - CT-P13, CT-P13 - Remicade, Remicade - CT-P13 | Intervention Type: BIOLOGICAL; Name: Remicade; Assigned to Arm(s): CT-P13 - Remicade, Remicade - CT-P13, Remicade - Remicade

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease
Brief Summary: This study is to assess noninferiority in efficacy and to assess overall safety of CT P13 compared to Remicade in patients with active Crohn's disease up to Week 54.


Options:
A: Arm Label: proactive infliximab optimization; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: standard of care infliximab dosing; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): proactive infliximab optimization, standard of care infliximab dosing
B: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Usual Care practice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Algorithm; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment Algorithm for Crohn's Disease | Intervention Type: OTHER; Name: Treatment Algorithm for Crohn's Disease; Assigned to Arm(s): Treatment Algorithm
D: Arm Label: CT-P13 - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: CT-P13 - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13, Biological: Remicade | Arm Label: Remicade - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: Remicade | Arm Label: Remicade - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13, Biological: Remicade | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): CT-P13 - CT-P13, CT-P13 - Remicade, Remicade - CT-P13 | Intervention Type: BIOLOGICAL; Name: Remicade; Assigned to Arm(s): CT-P13 - Remicade, Remicade - CT-P13, Remicade - Remicade

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Associations of Exposure to Bisphenol A With Blood Pressure and Epigenetic Change
Brief Summary: * Bisphenol A(BPA) is an endocrine disrupting chemical, which mimics the action of estrogen.
* Previous studies reported that BPA exposure is associated with increased risk of cardiovascular diseases.
* Exposure to BPA occur mainly through oral route, and epoxy coating of canned food is one of the well established source.
* The investigators hypothesis is that increased BPA exposure from canned beverage would disrupt normal physiology in a short term.
* In the present trial the investigators are to investigate whether increased BPA exposure by consuming canned beverage actually affect cardiovascular indices and epigenetic feature.
* For this aim, the investigators will conduct a cross-over trial.


Options:
A: Arm Label: Glass; Type: ACTIVE_COMPARATOR; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Arm Label: Can 1; Type: EXPERIMENTAL; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Arm Label: Can 2; Type: EXPERIMENTAL; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Intervention Type: OTHER; Name: Can 1; Assigned to Arm(s): Can 1, Can 2, Glass | Intervention Type: OTHER; Name: Can 2; Assigned to Arm(s): Can 1, Can 2, Glass | Intervention Type: OTHER; Name: Glass; Assigned to Arm(s): Can 1, Can 2, Glass
B: Arm Label: alcohol 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: alcohol | Arm Label: alcohol 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: alcohol | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: alcohol | Intervention Type: DIETARY_SUPPLEMENT; Name: alcohol; Assigned to Arm(s): alcohol 1, alcohol 2, control
C: Arm Label: Red Wine Polyphenols; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Red Wine Polyphenols 600mg/day | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Red Wine Polyphenols 600mg/day; Assigned to Arm(s): Red Wine Polyphenols | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Low- polyphenol diet; Type: OTHER; Interventions: Other: Two portions of fruit and vegetables per day (excluding berries and dark chocolate) | Arm Label: High-polyphenol diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate. | Intervention Type: OTHER; Name: Two portions of fruit and vegetables per day (excluding berries and dark chocolate); Assigned to Arm(s): Low- polyphenol diet | Intervention Type: OTHER; Name: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.; Assigned to Arm(s): High-polyphenol diet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preconditioning Shields Against Vascular Events in Surgery: A Multi-centre Feasibility Trial of Preconditioning Against Adverse Events in Major Vascular Surgery (Preconditioning-SAVES)
Brief Summary: Major vascular surgery involves operations to repair swollen blood vessels, clear debris from blocked arteries or bypass blocked blood vessels. Patients with these problems are a high-risk surgical group as they have generalized blood vessel disease. These puts them at risk of major complications around the time of surgery such as heart attacks , strokes and death. The mortality following repair of a swollen main artery in the abdomen is about 1 in 20. This contrasts poorly with the 1 per 100 risk of death following a heart bypass. Simple and cost-effective methods are needed to reduce the risks of major vascular surgery. Remote ischaemic preconditioning (RIPC) may be such a technique. To induce RIPC, the blood supply to muscle in the patient's arm is interrupted for about 5 minutes. It is then restored for a further five minutes. This cycle is repeated three more times. The blood supply is interrupted simply by inflating a blood pressure cuff to maximum pressure. This repeated brief interruption of the muscular blood supply sends signals to critical organs such as the brain and heart, which are rendered temporarily resistant to damage from reduced blood supply. Several small randomized clinical trials in patients undergoing different types of major vascular surgery have demonstrated a potential benefit. This large, multi-centre trial aims to determine whether RIPC can reduce complications in routine practice.


Options:
A: Arm Label: Precondition; Type: EXPERIMENTAL; Interventions: Procedure: Precondition | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Precondition; Assigned to Arm(s): Precondition
B: Arm Label: Remote ischaemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control to remote preconditioning group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic preconditioning
C: Arm Label: Remote ischaemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control to RIPC; Type: SHAM_COMPARATOR; Interventions: Procedure: Control to RIPC | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic preconditioning | Intervention Type: PROCEDURE; Name: Control to RIPC; Assigned to Arm(s): Control to RIPC
D: Arm Label: RIPC intervention; Type: EXPERIMENTAL; Interventions: Other: remote ischemic preconditioning | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: remote ischemic preconditioning; Assigned to Arm(s): RIPC intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
Brief Summary: This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS).


Options:
A: Arm Label: Human Mesenchymal Stromal Cells (hMSCs); Type: EXPERIMENTAL; Interventions: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells | Arm Label: Plasma-Lyte A (placebo); Type: PLACEBO_COMPARATOR; Interventions: Biological: Plasma-Lyte A | Intervention Type: BIOLOGICAL; Name: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells; Assigned to Arm(s): Human Mesenchymal Stromal Cells (hMSCs) | Intervention Type: BIOLOGICAL; Name: Plasma-Lyte A; Assigned to Arm(s): Plasma-Lyte A (placebo)
B: Arm Label: No dexamethasone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: GM-CSF | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: GM-CSF; Assigned to Arm(s): 1
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multinational, Randomized, Open Label Parallel Arm Trial With Blinded Outcome Adjudication Quantifying the Efficacy of SENATOR in Reducing Adverse Drug Reactions in Older Hospitalized Subjects
Brief Summary: Primary Objective: To quantify the benefits of the SENATOR decision support software on the reduction of ADR rates in older hospitalized patients. Secondary Objectives: To evaluate the effect of SENATOR with regard to use of appropriate non-pharmacological therapies in subjects with one core geriatric syndrome.

Tertiary Objectives: to examine the association of SENATOR use with subject survival, morbidity and health related quality of life.

Health Economic Objective: To examine the potential health economic consequences of using SENATOR.

There are two study phases:

Phase I: Prospective multinational, multicentre observational study to estimate the baseline adjudicated medical and surgical ADR rates by clinical subspeciality in 6 international sites.

Phase II: Prospective multinational, multicentre, block randomized, two parallel arm, open label, controlled trial, with blinded outcome ascertainment, of the efficacy of SENATOR software in reducing ADRs in older hospitalized subjects.


Options:
A: Arm Label: Pre-intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Mentored medication reconciliation quality improvement | Intervention Type: OTHER; Name: Mentored medication reconciliation quality improvement; Assigned to Arm(s): Intervention
B: Arm Label: Patients without intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinical pharmacy model | Arm Label: Patients with intervention; Type: EXPERIMENTAL; Interventions: Other: Clinical pharmacy model | Intervention Type: OTHER; Name: Clinical pharmacy model; Assigned to Arm(s): Patients with intervention, Patients without intervention
C: Arm Label: SENATOR; Type: EXPERIMENTAL; Interventions: Other: SENATOR software generated pharmacotherapy advice report. | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SENATOR software generated pharmacotherapy advice report.; Assigned to Arm(s): SENATOR
D: Arm Label: Before collarborative pharmaceutical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: After collarborative pharmaceutical care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Pharmaceutical Care | Intervention Type: OTHER; Name: Collaborative Pharmaceutical Care; Assigned to Arm(s): After collarborative pharmaceutical care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multinational, Randomized, Open Label Parallel Arm Trial With Blinded Outcome Adjudication Quantifying the Efficacy of SENATOR in Reducing Adverse Drug Reactions in Older Hospitalized Subjects
Brief Summary: Primary Objective: To quantify the benefits of the SENATOR decision support software on the reduction of ADR rates in older hospitalized patients. Secondary Objectives: To evaluate the effect of SENATOR with regard to use of appropriate non-pharmacological therapies in subjects with one core geriatric syndrome.

Tertiary Objectives: to examine the association of SENATOR use with subject survival, morbidity and health related quality of life.

Health Economic Objective: To examine the potential health economic consequences of using SENATOR.

There are two study phases:

Phase I: Prospective multinational, multicentre observational study to estimate the baseline adjudicated medical and surgical ADR rates by clinical subspeciality in 6 international sites.

Phase II: Prospective multinational, multicentre, block randomized, two parallel arm, open label, controlled trial, with blinded outcome ascertainment, of the efficacy of SENATOR software in reducing ADRs in older hospitalized subjects.


Options:
A: Intervention Type: BEHAVIORAL; Name: Integration of a team based clinical pharmacist; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Optimizing therapeutic treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Optimizing processes of care; Assigned to Arm(s): N/A
B: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: basic intervention; Type: SHAM_COMPARATOR; Interventions: Other: basic intervention | Arm Label: extended intervention; Type: SHAM_COMPARATOR; Interventions: Other: extended intervention | Intervention Type: OTHER; Name: basic intervention; Assigned to Arm(s): basic intervention | Intervention Type: OTHER; Name: extended intervention; Assigned to Arm(s): extended intervention
C: Arm Label: SENATOR; Type: EXPERIMENTAL; Interventions: Other: SENATOR software generated pharmacotherapy advice report. | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SENATOR software generated pharmacotherapy advice report.; Assigned to Arm(s): SENATOR
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Fecal transPlantAtion on MiCrobotia and hosT in Crohn's Disease
Brief Summary: Crohn's disease is a chronic and relapsing inflammatory bowel disease. Many data show that the intestinal flora is involved in the disease and it has been show that patients with Crohn's disease exhibit an abnormal fecal flora that might play a role in inflammation. The purpose of this study is to determine the effect of the fecal flora transplantation on Crohn's disease.


Options:
A: Arm Label: Fecal Transplantation; Type: EXPERIMENTAL; Interventions: Other: Fecal Transplantation | Arm Label: Sham Transplantation; Type: SHAM_COMPARATOR; Interventions: Other: Sham Transplantation | Intervention Type: OTHER; Name: Fecal Transplantation; Assigned to Arm(s): Fecal Transplantation | Intervention Type: OTHER; Name: Sham Transplantation; Assigned to Arm(s): Sham Transplantation
B: Arm Label: Metronidazole+doxycylcine+terbinafine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Doxycycline, Drug: Terbinafine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Terbinafine; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: FMT infusions; Type: ACTIVE_COMPARATOR; Interventions: Biological: FMT infusions | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo infusion | Intervention Type: BIOLOGICAL; Name: FMT infusions; Assigned to Arm(s): FMT infusions | Intervention Type: OTHER; Name: Placebo infusion; Assigned to Arm(s): Placebo arm
D: Arm Label: Study Participants; Type: EXPERIMENTAL; Interventions: Drug: Gut Microbial Transplantation | Intervention Type: DRUG; Name: Gut Microbial Transplantation; Assigned to Arm(s): Study Participants

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving the Nutrition Status of 6 to 8 Months Old Children Through Diet Diversification and Better Dietary Intakes in the Kabale and Kisoro Districts in South-Western Uganda
Brief Summary: Undernutrition and growth restriction due to poor diet and inadequate nutrient intake continues to be a global challenge, particularly in the developing countries including Uganda. The etiology of inadequate nutrient supply to infants may relate to lack of resources or knowledge or a combination of both. Poor nutrient intake and impaired growth may affect brain and cognitive development.

This study aims to evaluate nutrient intake, growth and cognitive function among children between 6 and 36 months living in the fertile Kabale and Kisoro region in south-western Uganda. The investigators hypothesize that nutrition education to mothers can bring about improved dietary intake and nutritional status among children aged 6-36 months.

A follow-up study was conducted during the period January - July 2022.


Options:
A: Arm Label: THPP-I; Type: EXPERIMENTAL; Interventions: Behavioral: THPP-I, Behavioral: EUC | Arm Label: Enhanced usual care (EUC); Type: OTHER; Interventions: Behavioral: EUC | Intervention Type: BEHAVIORAL; Name: THPP-I; Assigned to Arm(s): THPP-I | Intervention Type: BEHAVIORAL; Name: EUC; Assigned to Arm(s): Enhanced usual care (EUC), THPP-I
B: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Improving nutrition knowledge among mothers | Intervention Type: OTHER; Name: Improving nutrition knowledge among mothers; Assigned to Arm(s): intervention
C: Arm Label: Sonke CHANGE intervention condition; Type: EXPERIMENTAL; Interventions: Other: Sonke CHANGE intervention | Arm Label: Control condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Sonke CHANGE intervention; Assigned to Arm(s): Sonke CHANGE intervention condition
D: Arm Label: Intervention (iMBC/ECD + C-PrES); Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Mothers and Babies Course | Arm Label: Control (C-PrES); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Mothers and Babies Course; Assigned to Arm(s): Intervention (iMBC/ECD + C-PrES)

Answer: B